Boniface John J. 4
4 · SERA PROGNOSTICS, INC. · Filed Mar 28, 2024
Insider Transaction Report
Form 4
Boniface John J.
Chief Scientific Officer
Transactions
- Exercise/Conversion
Class A Common Stock
2024-03-28$0.91/sh+24,474$22,271→ 164,245 total - Sale
Class A Common Stock
2024-03-27$9.62/sh−3,753$36,104→ 139,771 total - Exercise/Conversion
Class A Common Stock
2024-03-27$0.91/sh+48,909$44,507→ 188,680 total - Sale
Class A Common Stock
2024-03-27$9.62/sh−48,909$470,505→ 139,771 total - Sale
Class A Common Stock
2024-03-28$9.04/sh−24,474$221,245→ 139,771 total - Exercise/Conversion
Stock Option (right to buy)
2024-03-27−48,909→ 24,474 totalExercise: $0.91Exp: 2024-12-29→ Class A Common Stock (48,909 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-03-28−24,474→ 0 totalExercise: $0.91Exp: 2024-12-29→ Class A Common Stock (24,474 underlying)
Footnotes (4)
- [F1]The transaction(s) reported on this Form 4 was/were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2023.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.85, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.58 to $9.24, inclusive. The reporting person will provide to the staff of the Securities and Exchange Commission, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
- [F4]The shares subject to this option are fully vested and exercisable.